Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...

Luana R. C. Pesco Koplowitz, M.D., Ph.D., Founder, President and Chief Scientific Officer of DUCK FLATS Pharma commented, “It is rewarding to engage with Oragenics on overall development strategy for ...

At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection ...

Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a ...

Neuren shares FDA feedback on NNZ-2591 development plans in HIE and PTHS, with next steps and management insights. The post ...

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...

Many times, when people think about joining clinical trials, getting a doctor’s referral is the first thing that comes to ...

Rocatinlimab, targeting the OX40 pathway, shows significant efficacy in moderate to severe atopic dermatitis, marking a new therapeutic class in disease management. Long-term melanoma data reveal ...

Boutique MedTech CRO gains access to unified eClinical platform with wholesale pricing, training, and joint marketing ...

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to treat overactive bladder symptoms, reduces hot flashes compared to the ...

HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...